Analysts See 30% Gains Ahead For The Holdings of XBI

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $83.80 per unit.

START SLIDESHOW:
10 ETFs With Most Upside To Analyst Targets »

With XBI trading at a recent price near $64.35 per unit, that means that analysts see 30.23% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XBI's underlying holdings with notable upside to their analyst target prices are Sangamo BioSciences Inc ( SGMO), ZIOPHARM Oncology Inc ( ZIOP), and Geron Corp. ( GERN). Although SGMO has traded at a recent price of $3.25/share, the average analyst target is 176.92% higher at $9.00/share. Similarly, ZIOP has 105.58% upside from the recent share price of $6.81 if the average analyst target price of $14.00/share is reached, and analysts on average are expecting GERN to reach a target price of $4.17/share, which is 96.51% above the recent price of $2.12. Below is a twelve month price history chart comparing the stock performance of SGMO, ZIOP, and GERN:

SGMO, ZIOP, and GERN Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
SPDR S&P Biotech ETF XBI $64.35 $83.80 30.23%
Sangamo BioSciences Inc SGMO $3.25 $9.00 176.92%
ZIOPHARM Oncology Inc ZIOP $6.81 $14.00 105.58%
Geron Corp. GERN $2.12 $4.17 96.51%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

More from Stocks

3 New Investing Myths That Must Be Busted

3 New Investing Myths That Must Be Busted

Why a Global Stock Market Crash Is Coming

Why a Global Stock Market Crash Is Coming

Dump All Your Disney Stock: Doug Kass Insider

Dump All Your Disney Stock: Doug Kass Insider

3 Must Know Market Insights From TheStreet's Jim Cramer Before Wednesday's Open

3 Must Know Market Insights From TheStreet's Jim Cramer Before Wednesday's Open

CHART: Even Consumer Staples Stocks Are Being Pummeled in Tuesday's Market Rout

CHART: Even Consumer Staples Stocks Are Being Pummeled in Tuesday's Market Rout